Standard smear microscopy and GeneXpert often miss drug‑resistant TB strains. Advanced genomic tools are emerging to close this diagnostic gap and improve patient outcomes.
Key Takeaways
- Traditional smear microscopy and GeneXpert miss many resistant TB strains.
- Whole‑genome sequencing and line‑probe assays provide higher detection accuracy.
- Delayed diagnosis leads to inappropriate treatment and increased transmission.
Introduction
Tuberculosis remains a leading cause of death worldwide, and drug‑resistant forms are on the rise. Yet most health systems still rely on conventional tests that frequently fail to identify resistant cases.
Limitations of Standard Tests
Smear microscopy, culture methods, and the widely used GeneXpert MTB/RIF assay primarily detect rifampicin resistance, overlooking resistance to other first‑line drugs. Consequently, many patients receive ineffective regimens, accelerating disease progression.
Historical Background
When multidrug‑resistant (MDR) TB was first reported in the 1990s, the World Health Organization promoted GeneXpert for rapid diagnosis. While the technology has evolved, resource‑constrained settings still depend on older, less sensitive methods.
Why This Matters
BozokMedia analysis shows that delayed detection of drug‑resistant TB not only raises mortality rates but also fuels community transmission, threatening national TB‑elimination goals.
"Advanced genomic sequencing unambiguously reveals resistance patterns, enabling clinicians to start the right therapy instantly," says Dr. John Patel, TB specialist.
Frequently Asked Questions
Question 1: Is GeneXpert available in all hospitals?
Answer: No, many rural and primary‑care facilities still rely on limited diagnostic tools.
Question 2: What new testing methods are emerging for drug‑resistant TB?
Answer: Whole‑genome sequencing, line‑probe assays, and digital PCR are currently considered the most reliable.
